Exelixis gains US OK for Cometriq in metastatic medullary thyroid cancer
This article was originally published in Scrip
Executive Summary
As expected, the US FDA gave its OK for Exelixis to market its tyrosine kinase inhibitor Cometriq (cabozantinib) as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC) – a decision that came after the US markets closed on 29 November.